Kura Oncology stock: Kura Oncology sets October 29 results date for Kura Oncology stock

Published on 10/22/2026 at 20:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q3 2026 revenue is forecast at USD 24.86 million. Kura Oncology stock costs EUR 8.79 on October 22, 2026 at 8:30 p.m. CEST.

Reporting date and market facts

Kura Oncology set its third-quarter 2026 results date for October 29, with revenue estimated at USD 24.86 million.
Second-quarter revenue was USD 20.87 million versus USD 20.16 million expected on August 12, 2026.
Kura Oncology stock costs EUR 8.79 at Lang & Schwarz on October 22, 2026 at 8:30 p.m. CEST.
The company had a USD 880.3 million market capitalization and a -2.93 price-to-earnings ratio on October 22, 2026.

KURA, US50127T1097, Illustration mit AI erstellt.

Kura Oncology (ISIN US50127T1097) is set to announce third-quarter 2026 results on October 29, with revenue estimated at USD 24.86 million, according to TradingView. Kura Oncology reported USD 20.87 million in second-quarter revenue against USD 20.16 million expected on August 12, 2026, while adjusted loss per share was USD 0.77 versus USD 0.88 expected, according to MarketBeat. Kura Oncology stock was trading at EUR 8.79 at Lang & Schwarz on October 22, 2026 at 8:30 p.m. CEST.

Revenue expectations move higher

The USD 24.86 million estimate for the third quarter stands 19.11 percent above the USD 20.87 million reported for the second quarter. That comparison points to a larger revenue base entering the October 29 update, although the estimate remains a forecast rather than a reported result.

Nasdaq range frames the stock

On Nasdaq, Kura Oncology was trading at USD 9.89 on October 22, 2026 at 2:33 p.m. EDT. Its 52-week range stood at USD 7.36 to USD 13.90 on October 16, 2026, placing the U.S. quote between the year's low and high. The Lang & Schwarz quotation remains the relevant euro view for investors in Germany.

Valuation and upcoming dates

Kura Oncology had a market capitalization of USD 880.3 million and a price-to-earnings ratio of -2.93 on October 22, 2026. Its next scheduled corporate event is the third-quarter results announcement on October 29, 2026, with the revenue estimate supplied by TradingView.

Comparison with peers

Kura Oncology: price-to-earnings ratio -2.93, market capitalization USD 880.3 million on October 22, 2026. Argenx (Nasdaq, USD): price-to-earnings ratio 33.70, market capitalization USD 55.5 billion on October 22, 2026. Fate Therapeutics (Nasdaq, USD): price-to-earnings ratio -1.98, market capitalization USD 243.0 million on October 22, 2026.

What the October 29 report can clarify

The revenue estimate gives the next results release a measurable threshold, while the second-quarter comparison provides the latest reported benchmark. Investors will also receive an update on KOMZIFTI, Kura Oncology's FDA-approved menin inhibitor, and the company's precision-medicine pipeline.

Euro quotation after hours

Kura Oncology stock was trading at EUR 8.79 at Lang & Schwarz on October 22, 2026 at 8:30 p.m. CEST. On Nasdaq, the stock was trading at USD 9.89 on October 22, 2026 at 2:33 p.m. EDT. The further course of trading is shown by the continuously updated real-time quote of Kura Oncology stock.